Bayer is Prepared to Settle Roundup Non-Hodgkin’s Lymphoma Cases
In response to the financial impact of over 18,000 pending lawsuits, Bayer is considering settlement as an option for resolving its current legal pressures.
The cases focus on the highly-publicized claims that Roundup, the popular herbicide that is produced by Bayer-owned Monsanto, causes non-Hodgkin’s lymphoma. Bayer has continuously defended the safety of their product, but is “open to a settlement as long as it resolves all Roundup litigation,” reported the Los Angeles Times. It is undetermined whether or not the theoretical settlement would apply to the existing 18,400 cases, or to all current and future Roundup-related litigation. A settlement amount has yet to be decided.
Settlement appears to be the most financially-responsible option for Bayer at this moment, as demand for Roundup — and the company’s shares — has decreased due to the lawsuits, bad weather limiting the growing season in North America and Europe, and agricultural trade disagreements between the United States and China. Due to the financial implications, Bayer is facing pressure to settle the cases not only from victims, but from investors as well.
Three Roundup cases have gone to trial, each resulting in recovery for the plaintiffs: A $25 million verdict, a $78 million verdict, and a $2 billion verdict (which was reduced to $86 million) in favor of non-Hodgkin’s lymphoma patients who were longtime users of the herbicide.
For more information on the Roundup settlement discussions, and to learn how Kershaw Cook & Talley can help, view our video on the subject. We will continue to provide updates on the state of Roundup litigation as the settlement discussion progresses.
If you or a loved one are a Roundup user and developed non-Hodgkin’s lymphoma, contact us today. To schedule a free case evaluation with our attorneys, use our contact form or call (916) 520-6639.